These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 27732335)

  • 1. Teriparatide Treatment in Patients With WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis: A Pilot Study.
    Välimäki VV; Mäkitie O; Pereira R; Laine C; Wesseling-Perry K; Määttä J; Kirjavainen M; Viljakainen H; Välimäki MJ
    J Clin Endocrinol Metab; 2017 Feb; 102(2):535-544. PubMed ID: 27732335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteocyte Protein Expression Is Altered in Low-Turnover Osteoporosis Caused by Mutations in WNT1 and PLS3.
    Wesseling-Perry K; Mäkitie RE; Välimäki VV; Laine T; Laine CM; Välimäki MJ; Pereira RC; Mäkitie O
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2340-2348. PubMed ID: 28379384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.
    Sumida K; Ubara Y; Hoshino J; Mise K; Hayami N; Suwabe T; Kawada M; Imafuku A; Hiramatsu R; Hasegawa E; Yamanouchi M; Sawa N; Takaichi K
    Osteoporos Int; 2016 Apr; 27(4):1441-1450. PubMed ID: 26525045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ANABOLIC BONE WINDOW WITH WEEKLY TERIPARATIDE THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS: A PILOT STUDY.
    Gopalaswamy V; Dhibar DP; Gupta V; Arya AK; Khandelwal N; Bhansali A; Garg SK; Agarwal N; Rao SD; Bhadada SK
    Endocr Pract; 2017 Jun; 23(6):657-661. PubMed ID: 28225309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Osteoporos Int; 2016 May; 27(5):1869-74. PubMed ID: 26759334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone material properties and response to teriparatide in osteoporosis due to WNT1 and PLS3 mutations.
    Fratzl-Zelman N; Wesseling-Perry K; Mäkitie RE; Blouin S; Hartmann MA; Zwerina J; Välimäki VV; Laine CM; Välimäki MJ; Pereira RC; Mäkitie O
    Bone; 2021 May; 146():115900. PubMed ID: 33618074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of daily teriparatide treatment for osteoporosis in men.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Osteoporos Int; 2015 Apr; 26(4):1303-9. PubMed ID: 25567777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.
    Gossiel F; Scott JR; Paggiosi MA; Naylor KE; McCloskey EV; Peel NFA; Walsh JS; Eastell R
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1302-1309. PubMed ID: 29365099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
    Mok J; Brown C; Moore AEB; Min SS; Hampson G
    Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
    Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
    J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength.
    Kleerekoper M; Greenspan SL; Lewiecki EM; Miller PD; Kendler DL; Maricic M; Keaveny TM; Kopperdahl DL; Ruff VA; Wan X; Janos B; Krohn K
    J Bone Joint Surg Am; 2014 Jun; 96(11):e90. PubMed ID: 24897747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.
    Cohen A; Stein EM; Recker RR; Lappe JM; Dempster DW; Zhou H; Cremers S; McMahon DJ; Nickolas TL; Müller R; Zwahlen A; Young P; Stubby J; Shane E
    J Clin Endocrinol Metab; 2013 May; 98(5):1971-81. PubMed ID: 23543660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel splice mutation in PLS3 causes X-linked early onset low-turnover osteoporosis.
    Laine CM; Wessman M; Toiviainen-Salo S; Kaunisto MA; Mäyränpää MK; Laine T; Pekkinen M; Kröger H; Välimäki VV; Välimäki MJ; Lehesjoki AE; Mäkitie O
    J Bone Miner Res; 2015 Mar; 30(3):510-8. PubMed ID: 25209159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.
    Finkelstein JS; Wyland JJ; Lee H; Neer RM
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1838-45. PubMed ID: 20164296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel large fragment deletion in PLS3 causes rare X-linked early-onset osteoporosis and response to zoledronic acid.
    Lv F; Ma M; Liu W; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X; Qiu Z; Li M
    Osteoporos Int; 2017 Sep; 28(9):2691-2700. PubMed ID: 28620780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
    Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
    J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
    Nakatoh S
    J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-pQCT study.
    Nishiyama KK; Cohen A; Young P; Wang J; Lappe JM; Guo XE; Dempster DW; Recker RR; Shane E
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2418-25. PubMed ID: 24684466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.